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The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-
analyses have suggested a strong association between cephalosporin use and CDI, and many national pro-
grammes on CDI control have focused on reducing cephalosporin usage. Despite reductions in cephalosporin
use, however, rates of CDI have continued to rise. This review examines the potential association of CDI with
cephalosporins, and considers other factors that influence CDI risk. EUCLID (the EUropean,multicentre, prospect-
ive biannual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhoea)
reported an increase in the annual incidence of CDI from 6.6 to 7.3 cases per 10000 patient bed-days from
2011–12 to 2012–13, respectively. While CDI incidence and cephalosporin usage varied widely across countries
studied, there was no clear association between overall cephalosporin prescribing (or the use of any particular
cephalosporin) and CDI incidence. Moreover, variations in the pharmacokinetic and pharmacodynamic properties
of cephalosporins of the same generationmake categorization by generation insufficient for predicting impact on
gut microbiota. A multitude of additional factors can affect the risk of CDI. Antibiotic choice is an important con-
sideration; however, CDI risk is associated with a range of antibiotic classes. Prescription of multiple antibiotics
and a long duration of treatment are key risk factors for CDI, and risk also differs across patient populations. We
propose that all of these are factors that should be taken into account when selecting an antibiotic, rather than
focusing on the exclusion of individual drug classes.
Introduction
The incidence of Clostridium difficile infection (CDI) has been
increasing markedly across Europe, North America and Asia
since 2000.1 Over 14000 cases of CDI were reported across all
National Health Service (NHS) hospitals in England between April
2014 and March 2015, with a CDI rate of 4.1 per 10000 patient
bed-days, an increase of 6% from the previous financial year.2
Between 2001 and 2011, the rate of C. difficile hospitalizations
in the USA increased nearly 3-fold, from 5.6 per 1000 discharges
in 2001 to 12.7 per 1000 discharges in 2011.3 According to data
from a surveillance study conducted by the US CDC, the estimated
number of incident cases of CDI in the USA in 2011 was 453000,
approximately two-thirds of which were healthcare-associated
infections.4 Increases in CDI have also been observed outside
the healthcare setting, with the proportion of CDI attributed to
community-associated infections ranging from 10% to 42%.5
The primary symptomof CDI is diarrhoea, althoughmany patients
will also have clinical features of colitis, including abdominal
cramps, fever and leucocytosis.6 CDI can vary in severity from
mild diarrhoea to pseudomembranous colitis. Country-specific,
30 day mortality estimates range from 2.8% to 29.8%.7 In a
prospective, multicentre study in 6522 patients from the UK,
30 day crude mortality (during a non-endemic period) was
16.6%, about half of which was directly attributable to CDI.8
Preventing C. difficile transmission in hospitals and community
settings is clearly a key priority in the prevention of CDI; however, it
is equally important that we achieve a better understanding of
the factors influencing the risk of developing CDI, including host
factors and antibiotic prescribing behaviour.9 CDI characteristic-
ally occurs in elderly patients with comorbidities in whom the
intestinal microbiota is disrupted due to antibiotic exposure.1
Three recent meta-analyses have evaluated the association
between antibiotic use and CDI.10–12 They reported that cepha-
losporins and clindamycin were most strongly associated with
hospital-associated CDI,10 while for community-associated infec-
tion, the strongest association was seen with clindamycin, cepha-
losporins and quinolones.11,12 These analyses may, however, be
subject to several potential sources of confounding and bias
from the included studies, and so reported associations between
CDI and specific antibiotics should be interpreted with caution.13
Possible confounding factors that could affect the analyses
include the presence of comorbidities, polypharmacy, dose and
duration of antibiotic treatment, and the use of multiple
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antibiotics.13 Additional potential sources of bias include sampling
bias (meaning that commonly prescribed antibiotics will be more
often reported as being associated with cases), selection of
inappropriate controls and misclassification of C. difficile. In add-
ition, studies may be open to clinical susceptibility bias, whereby
patients with illnesses requiring antibiotics may have inherent
increased risks of developing CDI, and cases may therefore be
falsely attributed solely to the clinically indicated use of antibio-
tics.13 Furthermore, there were between-study differences in
patient populations which, importantly, may have included differ-
ent levels of exposure to C. difficile.13 Notably, most of the data on
CDI have been collected from observational studies in the context
of outbreaks,14 and therefore may not reflect the risk of CDI in the
non-epidemic setting. Finally, the assumption that all antibiotics
within a given class are equally associated with CDI risk is not
well founded. Notably, differences in pharmacokinetics among
cephalosporins, particularly the route of excretion, can mean that
exposures of the gut microbiome and C. difficile vary markedly.
Antibiotic stewardship programmes have been established in
an attempt to optimize and sustain the utility of antibiotics; this
includes reducing the rates of resistance and hospital-associated
CDI. Some policies are focused on the restriction of cephalosporin
prescribing.15 For example, in 2008, the UK Department of Health
and Public Health England recommended that NHS hospitals
should develop restrictive antibiotic guidelines specifying the use
of narrow-spectrum agents alone or as combination therapy.16
The guidelines specifically highlighted that the use of clindamycin
and second- and third-generation cephalosporins should be
avoided, especially in the elderly; reduced use of fluoroquinolones
and carbapenems was also advocated.16
As data accumulate linking other broad-spectrum antibiotics
to CDI, we consider it timely to reassess the evidence for the
potential association of CDI with cephalosporins in Europe, to
explore whether cephalosporins still have a role in the era of CDI.
Pattern of cephalosporin use and incidence
of CDI across Europe
EUCLID (the EUropean, multicentre, prospective biannual point
prevalence study of CLostridium difficile Infection in hospitalized
patients with Diarrhoea) is the largest and most comprehensive
study of CDI epidemiology ever performed in Europe.17 The
study involved a total of 482 hospitals in 20 European countries.
Hospitals provided details on local policies for CDI testing and
reporting, and the laboratory methods used for CDI diagnosis,
together with local testing rates and CDI rates.17 Data were col-
lected from participating hospitals for the periods September
2011–August 2012 and September 2012–August 2013. In add-
ition, on two sampling days (one day in winter 2012–13 and one
day in summer 2013), hospitals sent all diarrhoeal samples sub-
mitted to their microbiology laboratory for standardized CDI
testing at national coordinating laboratories.17 The results
obtained by optimized testing were compared with local data.
EUCLID documented an increase in the reported annual inci-
dence of CDI from 6.6 cases per 10000 patient bed-days in 2011–
12 to 7.3 cases per 10000 patient bed-days in 2012–13.17
Furthermore, analysis of data from the two sampling days revealed
that 23%of CDI casesweremissed owing to lack of clinical suspicion
[i.e. samples that were not originally tested by the participating hos-
pital tested positive for CDI (defined as testing positive for both glu-
tamate dehydrogenase and C. difficile toxin) at the national
coordinating laboratory]. Overall, and taking into account false nega-
tives from local hospitals, each hospital missed an average of 82
cases per year. Across the 482 participating hospitals, there could
be as many as 40000 inpatients per year not diagnosed with CDI
as a result of suboptimal testing or lack of clinical suspicion.17
Cephalosporin use and incidence of CDI in individual
European countries
Data on the reported incidence of CDI by country across Europe for
2012–13 are presented in Figure 1. CDI incidence (given in cases
per 10000 patient bed-days) varied widely across Europe, ranging
from ,1 in Bulgaria to .20 in Finland.17 When the EUCLID CDI
rates are assessed in relation to data for overall cephalosporin
usage across Europe (in both hospital and community settings),
there is no clear association between cephalosporin prescribing
and incidence of CDI (Figure 1). Antibiotic surveillance data from
the ECDC show that although the use of any cephalosporin in the
community setting varied widely across countries, from a defined
daily dose (DDD) per 1000 inhabitants per day of 0.03 in the
Netherlands to 7.4 in Greece,18 there is no apparent association
with CDI incidence [r2¼0.020 (P¼0.584); Figure 1a]; in fact,
there is a weak inverse relationship, i.e. CDI incidence decreases
as cephalosporin use increases. For example, cephalosporin
usage in Sweden was among the lowest in Europe (0.2 DDD per
1000 inhabitants per day),18 while the reported CDI incidence
was among the highest (13.3 cases/10000 patient bed-days).17
In addition, considerable variation in cephalosporin usage was
observed across countries with similar reported CDI incidence,
such as the UK and France (0.3 and 2.3 DDD per 1000 inhabitants
per day, respectively). Confining the analysis to second- and third-
generation cephalosporins (the use of which should be restricted,
according to UK guidelines16) produces similar results, with no
apparent association observed between cephalosporin use and
CDI incidence [r2¼0.114 (P¼0.184); Figure 1a]. Similarly, there
is no significant correlation between cephalosporin use and
CDI incidence in the hospital setting [r2¼0.068 (P¼0.389);
Figure 1b]; apart from one country, as seen for community data
(Figure 1a), there is a weak inverse relationship between CDI inci-
dence and cephalosporin prescribing. For example, cephalosporin
usage in the hospital setting in Bulgaria was among the highest in
Europe (0.75 DDD per 1000 inhabitants per day), while reported
Figure 1. Incidence of CDI and overall cephalosporin use in (a) the community and (b) hospital settings during 2012–13. The text overlay reports usage
of first-, second-, third- and fourth-generation cephalosporins in EU/EEA countries in 2013, expressed as DDD per 1000 inhabitants and per day, if
available. Community/hospital usage of second- and third-generation cephalosporins (as a percentage of first-, second-, third- and
fourth-generation usage) is: Belgium, 92.8/53.6; Bulgaria, 82.1/87.0; Czech Republic, 94.5/NA; Finland, 2.6/77.9; France, 97.7/75.0; Germany, 97.8/NA;
Greece, 100/94.1; Hungary, 99.4/90.1; Ireland, 85.3/95.8; Italy, 96.4/78.8; Netherlands, 100/71.3; Poland, 95.2/NA; Portugal, 77.6/67.4; Slovakia, 95.6/
89.2; Spain, 99.4/NA; Sweden, 18.8/94.0; UK, 11.8/73.1. Data are from the ECDC.18 Regression analyses are based on least-squaresmeans. CDI incidence
data for 2012–13 are from Davies et al.17 aIncludes data for first-, second-, third- and fourth-generation cephalosporins.
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Table 1. Cephalosporins most commonly used across Europe in the year ending August 2013
Country
CDI incidence,
cases/10000
patient
bed-days
Total
cephalosporin
use, SUs, 1000s
Cephalosporin use, SUs, % (1000s) of total cephalosporin use in that country
cefuroxime
axetil
cefpodoxime
proxetil cefaclor cefixime cefalexin ceftriaxone cefuroxime cefazolin cefprozil cefadroxil ceftazidime other
Austria 4.1 13059 17.4 (2271) 20.0 (2609) 18.3 (2386) 10.9 (1422) 17.4 (2279) 2.0 (265) 8.1 (1058) 3.4 (444) — — 0.7 (88) 1.8 (237)
Belgium 4.0 10996 59.2 (6507) — ,0.05 (0.2) — 1.2 (129) 2.5 (275) 2.8 (306) 10.7 (1176) — 19.0 (2084) 2.7 (302) 2.0 (216)
Bulgaria 0.7 16702 29.7 (4958) 8.8 (1465) — 9.5 (1582) 12.8 (2145) 12.7 (2116) 3.0 (502) — 5.6 (929) — 0.2 (32) 17.8 (2972)
Czech Rep. 6.2 11048 62.7 (6928) — — — — 0.6 (64) 2.6 (287) 6.0 (668) 14.3 (1580) 8.4 (923) 1.2 (131) 4.2 (467)
Finland 28.7 19486 1.1 (211) — 0.3 (59) — 84.9 (16540) 1.3 (255) 12.2 (2381) — — — 0.2 (40) ,0.05 (0.6)
France 3.3 236373 10.0 (23708) 65.6 (155043) 3.3 (7878) 9.2 (21721) — 4.4 (10341) 0.4 (1043) 1.4 (3310) — — 0.6 (1432) 5.0 (11897)
Germany 11.0 204103 48.2 (98358) 8.4 (17056) 23.0 (46928) 3.6 (7328) — 2.7 (5531) 6.8 (13796) 2.1 (4208) — — 0.7 (1399) 4.7 (9500)
Greece 3.9 44798 48.4 (21680) — 23.0 (10300) 0.4 (199) — ,0.05 (20) 0.5 (221) — 27.1 (12162) — ,0.05 (12) 0.5 (204)
Hungary 15.5 14361 42.3 (6072) — 8.7 (1250) 16.9 (2420) — 4.3 (615) 2.4 (345) 1.9 (269) 16.8 (2411) — 0.3 (37) 6.6 (941)
Ireland 9.1 8492 15.4 (1306) 0.6 (51) 49.9 (4240) 4.9 (414) 22.6 (1917) 1.0 (83) 3.7 (314) 0.05 (4) — — 0.6 (51) 1.3 (113)
Italy 7.2 127431 3.4 (4285) 11.9 (15123) 10.6 (13507) 30.7 (39125) — 17.7 (22527) 0.3 (418) 4.5 (5787) — — 4.6 (5822) 16.4 (20850)
Netherlands 5.3 2913 5.9 (173) — 3.2 (94) — 2.3 (67) 10.2 (296) 30.6 (892) 32.2 (938) — — 8.8 (257) 6.8 (197)
Poland 8.2 74377 58.8 (43701) — 12.3 (9132) — — 2.6 (1923) 9.7 (7250) 2.6 (1952) — 7.8 (5770) 1.1 (787) 5.2 (3901)
Portugal 3.0 11544 33.2 (3837) — 10.8 (1246) 8.2 (952) — 7.9 (911) 1.8 (208) 6.8 (782) — — 1.6 (180) 29.7 (3427)
Romania 7.4 69306 45.6 (31592) — 11.9 (8227) 6.0 (4181) 16.4 (11376) 9.9 (6847) 0.7 (456) — — 4.3 (2997) 2.3 (1616) 2.9 (2014)
Slovakia 1.2 13901 61.7 (8575) — — 11.0 (1523) — 0.2 (24) 1.5 (202) 2.3 (315) 5.4 (746) 6.5 (904) 0.1 (14) 11.5 (1598)
Spain 3.2 58333 43.8 (25568) — — 19.1 (11130) — 4.1 (2403) 1.2 (676) 5.7 (3299) — — 1.7 (966) 24.5 (14293)
Sweden 13.3 3210 0 (0) — — — 0.4 (14) 1.2 (37) 4.5 (144) — — 51.6 (1657) 1.6 (52) 40.7 (1306)
UK 3.7 52992 0.9 (458) — 3.1 (1664) 0.4 (232) 80.8 (42842) 1.5 (802) 4.1 (2191) — — 0.8 (415) 1.2 (618) 7.1 (3769)
SU, standard unit.
CDI incidence data for September 2012 to August 2013 from Davies et al.17 Prescription data from IMS Health.
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CDI incidence was among the lowest (0.7 cases/10000 patient
bed-days).17,18 The lack of correlation between cephalosporin
use and CDI incidence is also apparent when the analysis is con-
fined to second- and third-generation cephalosporins [r2¼0.049
(P¼0.466); Figure 1b]. Under-testing/reporting and variations in
the reporting systems used in the different European countries
will clearly affect country-specific CDI rates, while the methods
employed to capture antibiotic use may also vary between coun-
tries. Despite the limitations inherent in this type of analysis, how-
ever, it seems unlikely that ‘corrected’ incidence datawould reveal
a correlation with cephalosporin prescribing, given the existent
data show a lack of correlation.
Use of different cephalosporins and incidence of CDI in
Europe
Table 1 shows the usage of specific cephalosporin antibiotics in
different European countries. These data also revealed no clear
associations between the reported CDI incidence from EUCLID17
and the use of any particular cephalosporin (Figure 2). There
were considerable variations in the use of particular drugs (as a
proportion of total cephalosporin use) across countries with similar
CDI incidence. For example, the use of cefuroxime axetil differed
markedly in France and Belgium (10.0% and 59.2%, respectively,
of cephalosporin prescriptions), although reported rates for CDI
were in the range of 1–4 cases/10000 patient bed-days in the
two countries. Similarly, ceftriaxone use differed in Italy (17.7%
of cephalosporin prescriptions) and Austria (2.0%), although CDI
incidence was similar (4–8 cases/10000 patient bed-days).
Furthermore, similar levels of use for some cephalosporins were
seen in countries with differing CDI incidence. For example, cefur-
oxime axetil accounted for 42%–46% of cephalosporin prescrip-
tions in Spain, Romania and Hungary, but CDI incidence differed
across these countries (1–4, 4–8 and 12–16 cases/10000 patient
bed-days, respectively). Similarly, use of ceftriaxone was similar
in Romania (9.9%) and Bulgaria (12.7%), although CDI incidence
differed (4–8 and,1 cases/10000 patient bed-days, respectively).
In Slovakia and the Czech Republic, the overall profiles of cephalo-
sporin use were similar, despite the differing incidence of CDI (1–4
and 4–8 cases/10000 patient bed-days, respectively).17
Although confounding factors, such as the use of other antibio-
tics, could affect CDI incidence, the data do not suggest a close
association between increased use of oral cephalosporins and
CDI incidence. Oral agents comprised approximately 80%–90%
of total cephalosporin use inmore than half of the countries stud-
ied, and CDI incidence ranged from 1–4 to .20 cases per 10000
patient bed-days in these countries. In countries where oral ceph-
alosporin use was less widespread (52%–66% overall), CDI inci-
dence also varied markedly (from ,1 to 12–16 cases per
10000 patient bed-days). Thus, these data suggest that deter-
mining the association between CDI risk and antibiotic usage is
more complicated than simply correlating the risk with the type
of drug, highlighting the need for more detailed analysis.
Principles underlying CDI risk
The risk of CDI is not uniform across all patient populations, but is
dependent on a number of issues, notably age, comorbidities and
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exposure to C. difficile. If C. difficile is not epidemic or has low
endemicity, then the risk of CDI is likely to be lower than in settings
in which bacterial transmission is high. Acquisition of C. difficile is
associated primarily with healthcare facilities, although
community-acquired severe disease has been reported among
individuals previously thought to be at low risk of infection.5 A
study using whole-genome sequencing has shown that, in an
endemic CDI setting, the majority of CDI cases are not closely
linked to previous cases.19 Furthermore, the rate of appearance
of new distinct C. difficile strains in the study population was con-
stant over a 3 year period, suggesting a close interplay between
strains found in the community and those found in hospitals.
Previous antimicrobial use is considered a key risk factor for CDI
among hospitalized patients20 and those in the community.21 A
systematic review showed that the incidence of CDI was asso-
ciated with the use of clindamycin, cephalosporins and penicillins,
and with the number of antibiotics a patient received, although
the authors expressed concerns about weaknesses with most of
the reported studies.20 A study of community-associated CDI
showed that exposure to antibiotic therapy in the previous
4 weeks, particularly multiple agents and oral cephalosporins,
was associated with a significantly increased risk of CDI, as was
hospitalization in the previous 6 months.21 However, approxi-
mately half the cases had not received antibiotic therapy in the
month before C. difficile detection, and approximately one-third
had neither exposure to antibiotics nor recent hospitalization.
These data have been corroborated in the Netherlands.22
Gut microbiota provides an important host defence against
C. difficile by inhibiting its establishment or proliferation.23
Studies in patients with CDI have reported that CDI is associated
with significant changes in the composition of faecal microbiota,
including, in some cases, the depletion of Gram-negative
Bacteroides spp., and reductions in normally abundant butyrate-
producing anaerobic bacteria in the Ruminococcaceae and
Lachnospiraceae families (part of the Clostridia class), suggesting
that they may also be involved in the defence against infection.24
Disruption of gut microbiota during antimicrobial use helps to cre-
ate conditions favourable for C. difficile expansion.25,26 Long or
repeated courses of antimicrobial therapy and the use of multiple
antimicrobials can increase the risk of CDI.27 Some broad-
spectrum antimicrobials have been implicated in CDI owing to
their wide-ranging effects on the microbiota. Importantly, the
impact of an antimicrobial on gut microbiota will depend on the
drug’s pharmacokinetic distribution and the concentration
achieved in the gut, as well as its antimicrobial activity.28
Are all cephalosporins the same with regard
to CDI risk?
Categorization of cephalosporins according to ‘generation’ is
insufficient for predicting impact on gut microbiota. Differences
in both pharmacokinetics (Table 2) and pharmacodynamic prop-
erties (Table 3) are apparent between different cephalosporins of
the same generation, as well as different generations. For the
majority of cephalosporins, excretion occursmainly via the kidney.
Most are excreted by glomerular filtration and this is particularly
pronounced for agents such as cefadroxil, cefalexin, cefuroxime,
ceftazidime and ceftobiprole. Biliary excretion is the main alterna-
tive route (Tables 2 and 3).29 In general, orally administered
cephalosporins are absorbed rapidly. Cefalexin, cefadroxil, cefra-
dine and cefaclor show almost complete absorption, whereas
absorption of cefixime and cefuroxime axetil is in the region of
40%–50%.30 These agents are acid stable,28 and they achieve
therapeutic concentrations in most tissues, including the gut.30
Therefore, it is reasonable to assume that these active com-
pounds in the gut may well influence the gut microbiota and so
affect the risk of CDI. Following parenteral administration, cepha-
losporins are distributed to the tissues, including bone and fluids,
including the pleural, synovial and cerebrospinal fluids.30 Many
cephalosporins are excreted in the bile, and although concentra-
tions tend to be relatively low (indicating that gut exposure will be
less than that achieved with orally administered cephalosporins),
therapeutic concentrations of the drug are generally achieved.30
For a few agents, such as cefoperazone and ceftriaxone, elimin-
ation occurs primarily or substantially via the biliary system, and
so gut exposure is likely to be higher than with other parenteral
cephalosporins (Table 2).29,30 Indeed, bile concentrations of ceftri-
axone reported in two studies31,32 were substantially higher than
those seen with other cephalosporins in other studies (Table 2).
Some studies have evaluated the concentrations of cephalos-
porins in the faeces, and shown differences between the various
agents (Table 3). In healthy volunteers, both cefixime and cefur-
oxime axetil were detected in faecal samples after being taken
orally, although marked differences in concentrations were
reported for the two drugs.33,34 Cefadroxil and cefaclor were not
detectable in faeces following oral administration.35,36 These dif-
ferences probably reflect variations in intestinal absorption
observed between these agents. Marked differences in faecal con-
centrations between individuals were observed following oral
administration of cefpodoxime proxetil.34 High concentrations
were reported in three volunteers, but cefpodoxime was not
detected in the faeces of the other seven, suggesting that intes-
tinal absorption and/or degradation of the drug varies between
individuals. The presence of cephalosporins in faeces has also
been detected following parenteral administration, with ceftriax-
one reported in faecal samples from healthy volunteers following
intravenous infusion.37 By contrast, ceftobiprole and ceftaroline
achieve low levels of gut exposure, with only minor effects on
gut microbiota.38,39 Indeed, no measurable concentrations of
either drug were detectable in faeces following intravenous
administration in healthy volunteers.38,39 Careful selection of par-
ticular cephalosporins, considering relevant gut pharmacokinetic
parameters, may therefore theoretically avoid disruption of the
normal gut microbiota and help to manage the risk of patients
developing CDI.
Effects of cephalosporins on C. difficile
The ability of a cephalosporin to inhibit C. difficile growth and toxin
production may reduce the risk of CDI, while also preventing the
emergence of resistance and recurrence. Currently, however,
there are comparatively few data available on the susceptibility
of C. difficile to cephalosporins. In general, cephalosporins have
poor in vitro activity against C. difficile (Table 4).40–52These studies
also showed that Gram-negative anaerobic bacteria, such as
Bacteroides spp., which make up a substantial proportion of the
gastrointestinal microbiota, typically had low susceptibility to
cephalosporins. Ceftaroline and ceftobiprole showed the greatest
activity against C. difficile isolates, with an MIC50 of 2–4 mg/L for
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Table 2. Summary of pharmacokinetic parameters for cephalosporins commonly used in Europe
Agent
Serum
t1
2
, h
Protein
binding,
%
Urinary
excretion,
%
Biliary
excretion,
%
Bile concentration,
mean+SD (range), mg/L
Dose (number of
doses)a Administration Citation
Cefadroxil 1.3–1.6 20 90 2 9.9b 1000 mg oral Karachalios and Charalabopoulos 200229
Cefalexin 0.8–1.0 10 90 0.5 (14.4–92)c [G] 500 mg every 6 h (×5) oral Sales et al. 197267
Cefazolin 1.8 80 65 0.2 17.1+8.5d 500 mg iv Brogard et al. 197568
14.0+4.7 [T] 500 mg iv Brogard et al. 197568
(0.85–21) [T] 1000 mg iv Nishida et al. 197669
46 [T] 1000 mg iv Ratzan et al. 197870
32.8 [G] 500 mg im Ram et al. 197371
92.1 [G] 500 mg every 6 h (×4) im Ram et al. 197371
Cefaclor 0.6 25 50–60 0.05 7.6+2.4 [T] 1000 mg oral Brogard et al. 198272
Cefprozil 1.45 40 76 — — — — —
Cefuroxime
axetil
1.3 33–50 90 — — — — —
Cefuroxime 1.3 35 95 0.5 10.3+2.4 [T] 500 mg iv Brogard et al. 198173
5.4 [G]/42.8 [BD] 1500 mg iv Thomas et al. 198174
4.8 [G]/9.0 [BD] 750 mg iv Severn and Powis 197975
Cefpodoxime
proxetil
2.0–3.6 20 80 — no data available — — —
Cefixime 3.0–4.0 65 50 10 56.9+70.9 [T] 200 mg oral Westphal et al. 199376
199.3 (8.8–1163.8) 200 mg twice daily (×4) oral Moorthi et al. 199077
Ceftriaxone 8.5 83–96 65 30–40 1078+158 [T]e 2 g every 12 h (×5) iv Brogard et al. 198831
4730 (2970–5880) [G] 2 g every 12 h (×5)f iv Hayton et al. 198632
Ceftazidime 1.8 17 80–90 3 21.2+9.2d,e 2000 mg iv Brogard et al. 198778
36.3+4.0 [T]e 2000 mg iv Brogard et al. 198778
34.1+24.8 [T]g 2000 mg iv Bouza et al. 198379
46.7 [T] 1000 mg iv Tanimura et al. 198380
3.9+1.1 [G]/31.8+3.7 [BD]e 1000 mg iv Shirmatsu et al. 198881
18.5 [G]/26.6 [BD]c 1000 mg iv Walstad et al. 198682
Ceftobiprole 3–4 16 80–90 — — — — —
Ceftaroline 2.5 20 88 — — — — —
BD, concentration in common bile duct; G, concentration in gall bladder bile; im, intramuscular; iv, intravenous; T, concentration in bile obtained from a T-tube or drain tube; t1
2
, terminal
elimination half-life.
Bile concentration data are shown for patients either undergoing or following cholecystectomyorwith cholecystolithiasis, unless otherwise indicated. Concentrations in bile obtained from
a T-tube or drain tube (indicated by T) are peak concentrations unless otherwise stated. Bile concentration data and associated population/dosing information are from the references
indicated; data for the other parameters are from Marshall and Blair 199983 except for ceftobiprole (Murthy et al. 200884) and ceftaroline (Summary of Product Characteristics85).
aSingle dose, unless otherwise indicated.
bAt 6–8 h after dosing.
cPatients with functioning gall bladder.
dPeak concentration in normal individuals, obtained by duodenal tubing.
eMean+SEM.
fTwo (of seven) patients received only three doses.
gAt 1 h after infusion.
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Table 3. Pharmacodynamic properties of cephalosporins commonly used in Europe
Generation Name
Route of
administration Route of elimination Distribution Effect on intestinal microbiota Faecal concentration
First cefadroxil/
cefadroxyl
(Duricefw)
oral almost completely absorbed
from the Gl tract, and not
metabolized
largest concentrations
observed in the duodenum,
with lower levels in the
stomach and jejunum, and
very low levels in the ileum
and colon when sampled
20 min after oral dosing in
mice86
administration to 20 healthy
individuals did not cause
measurable disturbance to
the colonic ecology, when
evaluating the effect of
cefadroxil 500 mg taken for
10 days.
not detected (,0.125 mg/L)
following administration
(500 mg twice daily for
10 days) in healthy
volunteers36
excreted unchanged in the
urine by renal glomerular
filtration, active tubular
secretion and active
tubular reabsorption87
cefadroxil is present in the
gallbladder and bile duct, as
well as at a high
concentration in bile29
effect on the intestinal
microbiotawasminor and the
microbiota was normal
2 weeks after withdrawal of
the drug36
First cefalexin/
cefalexin
(Keflexw)
oral almost completely absorbed
from the GI tract and not
metabolized
absorbed in the upper
intestine88
CDAD has been reported with
use of nearly all antibacterial
agents, including
cefalexin (SPC)
—
excreted in the urine
unchanged by renal
glomerular filtration and
active tubular
secretion (SPC)
cefalexin excreted in bile
accounts for 0.29% of the
administered dose29
7/12 patients with urinary tract
infection treated with oral
cefalexin became faecal
carriers of Pseudomonas
aeruginosa; this acquisition
rate was significantly higher
than in patients who received
no antibiotics89
First cefazolin parenteral not metabolized biliary excretion is low and
amounted to 0.03% of the
administered dose; the
concentration is about the
same or slightly in excess of
the simultaneous serum
level, provided that the
biliary tract is not
obstructed29
in patients undergoing a
gastrectomy, prophylactic
cefazolin caused a significant
decrease in the numbers of
Bifidobacterium, Lactobacillus
and Eubacterium spp.; there
was a significant suppression
of streptococci and an
increase in enterococci90
—
excreted in amicrobiologically
active form in the urine,
mainly by renal glomerular
filtration (SPC)
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Second cefaclor (Ceclorw;
Distaclorw;
Keflorw;
Raniclorw)
oral almost completely absorbed
from the GI tract and not
metabolized
actively excreted in bile of dogs
at a concentration more
than sufficient to be
effective against susceptible
pathogens29
aerobic intestinal microbiota
was unchanged during and
after cefaclor administration,
while a minor impact on the
anaerobic intestinal
microbiota was observed; the
anaerobic intestinal flora
returned to its normal state
within 1 week
not detected following
administration (250 mg
every 8 h for 7 days) in
healthy volunteers35
excreted in the urine
unchanged by renal
glomerular filtration, active
tubular secretion and
active tubular
reabsorption (SPC)
no new colonization with
cefaclor-resistant
microorganisms was
observed and no side effects
were registered during the
investigation period35
Second cefprozil oral elimination is predominantly
renal by glomerular
filtration and tubular
secretion; about 10%of the
drug is eliminated by
extrarenal mechanisms91
cefprozil shows penetration
into tonsillar and adenoidal
tissue at concentrations
equivalent to nearly 40% of
those in the plasma at 3 h
after oral dosing92
there was a moderate decrease
in Enterobacteriaceae and a
slight increase in enterococci,
staphylococci and
bacteroides during cefprozil
administration in healthy
volunteers (500 mg twice
daily for 8 days)91
—
nometabolites were detected
in the urine91
penetration of cefprozil into
blister (interstitial) fluid
(simulating penetration into
skin and soft tissues) was
similar to cefaclor, although
the time during which
cefprozil concentration
exceeded MIC90 was usually
at least two times greater
than cefaclor for common
pathogens, including
Streptococcus pneumoniae
and Staphylococcus
aureus92
numbers of bacteria returned to
normal 4 days after the last
study day91
Continued
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Table 3. Continued
Generation Name
Route of
administration Route of elimination Distribution Effect on intestinal microbiota Faecal concentration
Second cefuroxime axetil
(Zinatw)
oral absorbed from the GI tract
and rapidly hydrolysed in
the intestinal mucosa and
blood to release
cefuroxime into the
circulation
concentrations of cefuroxime
in excess of the MIC for
common pathogens can be
achieved in the tonsilla,
sinus tissues, bronchial
mucosa, bone, pleural fluid,
joint fluid, synovial fluid,
interstitial fluid, bile, sputum
and aqueous humour (SPC)
in healthy volunteers, numbers
of enterococci increased
while the levels of
Enterobacteriaceae remained
stable during cefuroxime
axetil administration (250 mg
twice daily for 10 days); the
numbers of clostridia were
slightly decreased, whereas
other anaerobes were
unaffected34
detected in the faeces of all 10
healthy volunteers
following administration
(250 mg twice daily for
10 days), but on only one or
two sampling occasions in
three individuals; on day 7,
mean concentration was
0.57 mg/kg (range:
,0.125–0.84), with
detectable levels in nine
individuals34
not metabolized, and
excreted via the kidneys by
glomerular filtration and
tubular secretion (SPC)
intestinal microbiota had
returned to normal 2 weeks
after stopping treatment34
cefuroxime axetil (250 mg twice
daily for 10 days) significantly
decreased staphylococci,
Enterobacteriaceae and
clostridia in patients suffering
from acute exacerbation of
chronic bronchitis93
Second cefuroxime
(Zefuw;
Zinacefw;
Ceftinw;
Biofuroksymw;
Xorimaxw)
parenteral metabolically stable and
eliminated primarily via the
kidneys by glomerular
filtration and tubular
secretion94
biliary levels are lower than
simultaneous serum levels,
but at levels that exceeded
the MIC for many common
gallbladder pathogens,
including Escherichia coli
and salmonellae29
— —
Third cefpodoxime
proxetil
oral a prodrug that is absorbed
from the GI tract and
de-esterified to its active
metabolite, cefpodoxime
body tissue and fluid
distribution of cefpodoxime
is extensive after
administration of
cefpodoxime proxetil95
cefpodoxime proxetil
administration (200 mg twice
daily for 7 days) strongly
reduced the numbers of
streptococci,
Enterobacteriaceae and
clostridia in 10 healthy
volunteers, while there was a
marked increase in
enterococci96
not detected in faeces of
seven healthy volunteers
following oral
administration (200 mg
twice daily for 7 days), but
high concentrations were
found in three individuals on
days 4, 7 and 9, whenmean
concentrations were 220,
430 and 140 mg/kg,
respectively34
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approximately 50% of the
administered dose is
absorbed systemically
2/10 individuals became
colonized by high levels of
staphylococci and yeasts
during cefpodoxime proxetil
administration, and five
volunteers were colonized by
Clostridium difficile after the
end of administration96
undergoes minimal
metabolism, and is
eliminated primarily by
renal excretion. Any
unabsorbed drug is
degraded in the GI tract
and excreted in the
faeces95
2 weeks after cefpodoxime
withdrawal, intestinal
microbiota had returned to
normal (except for two
subjects with C. difficile)96
Third cefixime (Fixxw;
Zifiw; Supraxw)
oral almost completely absorbed
from the GI tract, and not
metabolized
after administration of
cefixime, high antibiotic
levels were achieved in bile
and gallbladder tissue, even
13–17 h after the last
application77
there was a marked decrease in
the numbers of streptococci
and E. coli, and an increase in
the numbers of enterococci
during the administration of
cefixime; in the anaerobic
microbiota, the numbers of
cocci, clostridia and
bacteroides were suppressed,
while there were minor
changes in the numbers of
bifidobacteria. C. difficile was
isolated in five individuals on
day 7, but cytotoxin was only
detected in one person33
concentrations in faeces
increased during
administration (200 mg
twice daily for 7 days) in 10
healthy volunteers; one
individual had detectable
concentrations on day 2,
three on day 4, and eight on
day 7, which were in the
range 237–912 mg/kg33
excreted in the urine
unchanged by renal
glomerular filtration (SPC)
the intestinal microbiota was
normalized within 2 weeks
after treatment cessation33
Third ceftriaxone
(Rocephinw)
parenteral eliminated mainly as
unchanged drug,
approximately 60% of the
dose being excreted in the
urine (almost exclusively by
glomerular filtration) and
the remainder via the
biliary and intestinal
tracts (SPC)
average fraction of a dose of
ceftriaxone excreted in bile
is estimated as 15%29
had a profound effect on the
faecal flora; none of the
Gram-negative bacilli, only
24% of aerobic Gram-positive
organisms and only 10% of
anaerobes persisted during
ceftriaxone administration97
mean concentrations
152 mg/kg (range, 0–657)
and 258 mg/kg (0–806) on
days 4 and 8, respectively,
following iv infusion
(2000 mg once daily) for
7 days in healthy
volunteers37
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Table 3. Continued
Generation Name
Route of
administration Route of elimination Distribution Effect on intestinal microbiota Faecal concentration
Third ceftazidime
(Meezatw;
Fortumw;
Fortazw)
parenteral excreted unchanged in the
urine by glomerular
filtration (SPC)
concentrations in excess of the
MIC for common pathogens
can be achieved in tissues
such as bone, heart, bile,
sputum, aqueous humour,
and synovial, pleural and
peritoneal fluids (SPC)
in volunteers who received iv
ceftazidime at a dose of
4000 mg for 1 day,
Enterobacteriaceae and
lactobacilli decreased
considerably, while no effect
on other microorganisms in
the flora could be observed98
—
biliary excretion accounts for
,1% of non-renal excretion
of ceftazidime in healthy
individuals29
Fifth ceftobiprole
(Zevteraw;
Mabeliow)
parenteral primarily excreted via the
kidneys, resulting in
relatively low levels of
intestinal exposure and
only minor disruption of
intestinal anaerobes38,84
binds minimally (16%) to
plasma proteins, and
binding is independent of
the drug and protein
concentrations84
in comparison with other
cephalosporins, ceftobiprole
demonstrates relatively good
activity against clostridia,
including some strains of
C. difficile41,99
not detected following iv
administration (500 mg
every 8 h for 7 days) in
healthy volunteers38
undergoes minimal hepatic
metabolism84
in healthy volunteers,
ceftobiprole had no
significant ecological impact
on the human intestinal
microbiota38
ceftobiprole and ceftobiprole
medocaril did not promote
growth of or toxin production
by C. difficile in mouse caecal
contents, whereas
ceftazidime, cefoxitin,
ceftriaxone, cefotaxime and
ertapenem did53
this was attributable to
inhibitory activity against
C. difficile and sparing of
anaerobic microbiota
Fifth ceftaroline
(ZinforoTM)
parenteral primarily eliminated by the
kidneys
after 12 healthy subjects
received 600 mg ceftaroline
iv twice daily for 7 days, no
measurable concentrations
of drug were found in faeces
on days 1, 2, 5, 7, 9, 14
or 2139
therewas aminor impact on the
numbers of E. coli strains,
while the numbers of
enterococci and Candida
albicans strains were not
affected39
not detected following iv
administration (600 mg
every 12 h for 7 days) in
healthy volunteers39
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both agents;40,41,52 one review also reported good activity of cef-
prozil.42 As noted earlier, however, most cephalosporins are
excreted primarily by the kidney, and thus antimicrobial activity
against C. difficile may be of limited clinical relevance for drugs
that do not penetrate the gut at therapeutic levels (Table 3).
The impact of different cephalosporins on C. difficile growth
and toxin production in the gut has also been investigated using
animal and in vitro models.40,53,54 Nerandzic and Donskey53
showed that neither ceftobiprole nor its prodrug ceftobiprole
medocaril promoted the growth of C. difficile or the production
of C. difficile toxin in a mouse model of caecal C. difficile coloniza-
tion. By contrast, ceftazidime, cefotaxime and ceftriaxone were
pro-C. difficile. In an in vitro model of the human gut, exposure
to cefotaxime, with or without its active metabolite desacetylce-
fotaxime, led to C. difficile proliferation and increased levels of
cytotoxin.54 Reductions in gut bacteria were also observed, par-
ticularly in Bifidobacterium and Bacteroides spp., suggesting that
these genera may play a role in colonization resistance.54 A more
recent study using the in vitro human gutmodel showed that both
ceftaroline and ceftriaxone induced C. difficile spore germination,
proliferation and toxin production.40 Both spore germination and
growth of C. difficile were delayed with ceftaroline compared with
ceftriaxone, although the reasons for this are unclear. The produc-
tion and release of C. difficile toxin was also delayed with ceftaro-
line, probably reflecting differences in the balance between
antibiotic-mediated effects on the gut microbiota and on
C. difficile for the two agents.40
The concentrations and activity of cephalosporins in the gut
could also be affected by the presence of b-lactamases expressed
by commensal gut bacteria, such as Bacteroides fragilis, although
the clinical effect of such activity is unclear.55 Combining cepha-
losporins with b-lactamase inhibitors in the context of active CDI
is intended to overcome this and to broaden the spectrum of
activity of the drug.56–60 For example, the combination of ceftazi-
dime with the non-b-lactam, b-lactamase inhibitor avibactam
significantly improved the in vitro activity of ceftazidime against
anaerobic bacteria, such as C. difficile and B. fragilis.59,60 In a
small study in 12 healthy volunteers, ceftazidime/avibactam
(2000 g/500 g every 8 h on days 1–6) was shown to have a signifi-
cant effect on the intestinal microbiota, with reductions in the
numbers of Enterobacteriaceae, lactobacilli and bacteroides in
the faeces.56 Notably, toxigenic strains of C. difficile were reported
in five volunteers, with four reporting loose stools. A similar study
of ceftaroline/avibactam (600 mg/600 mg every 8 h on days 1–6)
in 12 healthy volunteers found that while numbers of Escherichia
coli and lactobacilli in the faeces were reduced, there was no not-
able effect on bacteroides. A toxigenic C. difficile strain was
reported in one patient, but this was not associated with adverse
events.57
Taken together, these differences likely mean that some
cephalosporins present a lower CDI risk than others. Agents that
are primarily excreted via the kidneys result in relatively low levels
of intestinal exposure, and only minor disruption of intestinal
microbiota, especially anaerobes. Moreover, although many
cephalosporins have poor activity against C. difficile, some agents
display relatively high activity and are able to inhibit the growth of
C. difficile, thus minimizing the likelihood of CDI.40,53
All of the above factors should be taken into consideration
when assessing the risk associated with CDI from cephalosporin
use. It is important to note that the risk of CDI is not the same
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for all patients. For example, in a CDC surveillance study, the risk of
CDI was markedly greater in patients aged 65 years and over than
in those younger than 65 years [rate ratio¼8.65 (95% CI¼8.16–
9.31)].4 Moreover, elderly individuals, patients with severe or mul-
tiple comorbidities (modified Horn index score of 3 or 4) and those
receiving additional antibiotics are at an increased risk of recurrent
CDI.61 Thus, using a cephalosporin in a 25 year old patient with
pneumonia, with no other risk factors for CDI, in a low-endemic
CDI incidence country or setting is likely to carry considerably less
risk than using a cephalosporin in an 80 year old patient with mul-
tiple comorbidities; in a hospital setting where the background
incidence of CDI is high, such risk may be even greater. The risk
of CDI may be further mitigated by careful selection from the
array of cephalosporins available, noting their pharmacokinetic
parameters (such as the achieved gut levels), effects on micro-
biota and impact on C. difficile growth and toxin production.
Antibiotic selection pressure for C. difficile
New evidence from detailed molecular epidemiological studies of
over 3000 C. difficile isolates from the UK and other countries
suggests that fluoroquinolones have provided a key selection
pressure for epidemic clones. Compelling antibiotic prescribing
data help to explain the rise and fall of CDI incidence in the UK.
In response to UK guidance recommending restriction of cephalo-
sporin and fluoroquinolone use,16 marked changes occurred in
antibiotic prescribing. During 1998–2014, fluoroquinolones (but
not total antibiotic prescribing) correlated strongly with the inci-
dence of CDI.62 Coincident with these declines, the types of preva-
lent C. difficile strains also changed markedly. Of particular note is
that the decrease in CDI incidence was due to substantial reduc-
tions in C. difficile clones that were resistant to fluoroquinolones;
the prevalence of fluoroquinolone-resistant clones declined from
67% to 3%, but fluoroquinolone-susceptible clones persisted.
Although reductions in cephalosporin prescribing also correlated
with CDI incidence, the clone-specific effects cannot sensibly be
explained by changes in cephalosporin use, because C. difficile is
generally resistant to these antibiotics. Thus, if cephalosporin
prescribing imparted a selection pressure on C. difficile, then
decreases in all strain types would have been expected to occur.
The importance of fluoroquinolone restriction as a potential con-
trol measure was also manifested by significant decreases
Table 4. In vitro susceptibility of Clostridium difficile to cephalosporins commonly used in Europe
Agent Isolates tested, n
MIC, mg/L
Citationrange MIC50 MIC90
Cefadroxil — no data no data no data —
Cefalexin 36 — 64a 128a Thornsberry 199242
Cefazolin 26 ≤0.5–.128 16 32 Pierard et al. 198943
17 — 25.0 — Simon et al. 198844
Cefaclor 10 16–.32 .32 .32 Spangler et al. 199445
12 32–.64 64 .64 Bauernfeind 199146
36 — 32–128 32–.100 Thornsberry 199242
Cefprozil 36 — 4a 4–8a Thornsberry 199242
12 64–.64 64 .64 Bauernfeind 199146
Cefuroxime 26 2–.128 .128 .128 Pierard et al. 198943
10 16–.32 .32 .32 Spangler et al. 199445
12 64–.64 .64 .64 Bauernfeind 199146
73 64–≥256 ≥256 ≥256 Chow et al. 198547
401 .256b — — Noren et al. 201048
51 — 512 512 Freeman and Wilcox 200149
Cefpodoxime 10 16–.32 .32 .32 Spangler et al. 199445
12 64–.64 .64 .64 Bauernfeind 199146
Cefixime 12 .64 .64 .64 Bauernfeind 199146
Ceftriaxone 26 ≤0.015–.64 32 64 Snydman et al. 201152
42 2–64 32 32 Chow et al. 198547
60 8–128 32 64 Baines et al. 201340
86 8–256 48 256 Buchler et al. 201450
Ceftazidime 73 16–≥256 32 64 Chow et al. 198547
NR 32–256 64 128 Rolfe and Finegold 198151
Ceftobiprole 30 1–8 4 8 Ednie et al. 200741
Ceftaroline 26 ≤0.015–8 2 8 Snydman et al. 201152
60 0.125–16 4 4 Baines et al. 201340
NR, not reported.
aMode values from several studies.
bAll isolates.
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(P,0.001) in the incidence of CDIs caused by fluoroquinolone-
resistant strains for the subgroups of patients with and without a
likely hospital donor. No such effect was seen in respect of
fluoroquinolone-susceptible CDIs. These compelling data empha-
size the potential value of fluoroquinolone restriction as a key com-
ponent of antimicrobial stewardship in controlling CDI.62
Clinical evidence of CDI risk with
cephalosporins
Recent meta-analyses have sought to establish the strength of
association between the use of broad-spectrum antibiotics and
CDI.10–12 Overall, findings from the three analyses were similar,
with clindamycin showing the strongest association with CDI in
both hospital and community settings.10–12 The risk of CDI with
cephalosporins was similar to that observed with other classes
of antibiotics, such as quinolones/fluoroquinolones,10,11 carbape-
nems10 and penicillins.11 Slimings and Riley10 assessed the asso-
ciation between antibiotic use and hospital-acquired CDI. The
meta-analysis involved one cohort and 13 case–control studies,
of which all except one were of high or moderate quality.
Overall, the risk of CDI with cephalosporins (OR¼1.97; 95%
CI¼1.21–3.23) was lower than with clindamycin (OR¼2.86;
95% CI¼2.04–4.02) and similar to that with carbapenems
(OR¼1.84; 95% CI¼1.26–2.68) and quinolones (OR¼1.66; 95%
CI¼1.17–2.35).10 Analysis of cephalosporins by generation
showed that the risk of CDI was greatest with third-generation
agents (OR¼3.20; 95% CI¼1.80–5.71), and lower with second-
generation (OR¼2.23; 95% CI¼1.47–3.37) and fourth-
generation drugs (OR¼2.14; 95% CI¼1.30–3.52). In addition,
the analysis showed that penicillin combination antibiotics, such
as piperacillin/tazobactam, were associatedwith an increased risk
of hospital-associated CDI (OR¼1.54; 95% CI¼1.05–2.24).10
The other two meta-analyses evaluated the association
between community-associated CDI and antibiotic use.11,12 All
of the studies used a case–control design, except for one cohort
study, and there was some overlap of studies between the two
reports. Deshpande et al.11 reported that the risk of CDI with
cephalosporins (OR¼4.47; 95% CI¼1.60–12.50) was less than
with clindamycin (OR¼20.43; 95% CI¼8.50–49.09) and similar
to that with fluoroquinolones (OR¼5.50; 95% CI¼4.26–7.11)
and penicillins (OR¼3.25; 95% CI¼1.89–5.57). The
meta-analysis did, however, show a high degree of heterogeneity
among the included studies, particularly those in the analyses of
the antibiotics cephalosporins, clindamycin and penicillins.11 In
the other meta-analysis, the risk of community-associated CDI
with cephalosporins, monobactams and carbapenems
(OR¼5.68; 95% CI¼2.12–15.23) was less than with clindamycin
(OR¼16.80; 95% CI¼7.48–37.76) and similar to that observed
with fluoroquinolones (OR¼5.50; 95% CI¼4.26–7.11).12
In all cases, analysis of the association between cephalosporin
use and CDI has been based on the inclusion of all cephalosporins
as a single group, or analysing by generation; however, as dis-
cussed above, this can bemisleading, given themarked variations
observed between different cephalosporins, including those of the
same generation. Unfortunately, CDI data for individual cephalos-
porins are largely absent from the literature. Furthermore, the
studies included in the three meta-analyses were all observa-
tional studies and were therefore prone to confounding and
bias. Heterogeneity was commonly observed, with all three
meta-analyses reporting substantial heterogeneity between
studies in most of the antibiotic subclass analyses. Between-
study heterogeneity was particularly marked for cephalosporins
in both the hospital-based10 and community-based11 analyses,
and was still present when cephalosporins were analysed by gen-
eration.10 Notwithstanding the differences among cephalosporins
noted in this review, variations in study populations and method-
ologies, case definitions and C. difficile strains may all contribute
to the between-study heterogeneity.13
One major limitation of previous studies is the failure to
account for the propensity of clinicians to prescribe specific anti-
biotics for certain conditions, such as the use of cephalosporins
and macrolides for pneumonia. It is therefore useful for analyses
to focus on a single disease. A prospective study in 107 patients
with community-acquired pneumonia (CAP) found that while
the choice of antimicrobial therapy was not associated with
acquisition of C. difficile, length of treatment and previous hospi-
talization were risk factors; however, it should be noted that this
study examined C. difficile colonization and there were no reports
of active CDI in this study.63 A further prospective, observational
cohort study of 1883 patients with CAP from Edinburgh, UK,
used Cox proportional hazards regression analysis to assess risk
factors for the development of CDI. Age, duration of hospitaliza-
tion, total number of antibiotics and duration of antibiotic therapy
were shown to be major risk factors for CDI. Consistent with the
previous study, however, antibiotic class was not an independent
predictor of CDI when adjusted for these risk factors.64
Antibiotic strategies to reduce CDI risk
The points explored in this review raise the concern that attempts
to reduce CDI risk by restricting the use of a small number of anti-
biotic classes (such as cephalosporins and clindamycin) may fail
to reduce the overall incidence of CDI, because those agents
may be replaced by antibiotics with a similar risk of CDI (such as
fluoroquinolones and b-lactam/b-lactamase inhibitors). Thus, a
balanced approach to antibiotic stewardship may be more bene-
ficial. This should include reducing unnecessary antibiotic use,
reducing prolonged antibiotic duration, avoiding the use of mul-
tiple antibiotic classes and promoting de-escalation of broad-
spectrum therapy as soon as possible. Such an approach would
promote the use of antibiotic agents carrying the lowest risk of
CDI whenever possible, but without mandating a homogeneous
approach to prescribing based on a simplistic classification of
‘good’ or ‘bad’ antibiotics. Moreover, increasing the heterogeneity
of antibiotic prescribing is associated with reduced selection pres-
sure and the emergence of resistance.65,66A study conducted in a
single intensive care unit showed that antibiotic prescribing proto-
cols for ventilator-associated pneumonia that led to highly homo-
geneous prescribing were associated with marked increases in
carbapenem-resistant Acinetobacter baumannii and extended-
spectrum b-lactamase-producing Enterobacteriaceae.65 A
meta-analysis showed that increased heterogeneity of prescribing
was beneficial in reducing the incidence of all hospital-acquired
infections and resistant infections.66 Positive effects were also
observed for most pathogens, and effects were particularly
pronounced when baseline levels of resistance were low.66
Therefore, selective use of cephalosporins, as part of a stewardship
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programme that delivers antibiotic diversity, could be an effective
and well-tolerated therapeutic option.
Summary
Reducing the incidence of CDI presents an important challenge,
given the multitude of factors that can affect the risk of CDI.
Choice of antibiotic treatment is an important consideration
when it comes to reducing risk; however, CDI risk is associated
with a range of antibiotic classes, and is clearly not specific to
cephalosporins. Indeed, there is evidence that use of fluoroquino-
lones, rather than of cephalosporins, has provided a much more
profound selection pressure for particular epidemic C. difficile
clones. In addition, the prescription of multiple antibiotics and
an inappropriate length of treatment should be considered key
risk factors for CDI. Furthermore, the risk is not the same across
all patient populations, and is likely to differ at the national,
local and care centre levels. All of these are factors that should
be taken into account when selecting an antibiotic. The assess-
ment of CDI risk simply based only on drug class is uninformative,
because each drug (evenwithin the same class)may have distinct
pharmacokinetic and pharmacodynamic properties, which should
be given the appropriate weighting in clinical decision-making. For
instance, a broad-spectrum antibiotic with an appropriate phar-
macokinetic profile (e.g. one that is eliminated predominantly by
the kidneys and hence may limit exposure in the gut) may be a
suitable choice for urgent empirical therapy. Reducing the inci-
dence of CDI is best achieved by concentrating on rational pre-
scribing, reducing the duration of antibiotic use and adhering to
good infection control practices, rather than by focusing on the
exclusion of individual drug classes. Indeed, antibiotic class exclu-
sion will likely lead to reduced prescribing diversity, which in turn
may drive resistance.
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